Skip to content
An update from Johnson & Johnson

Johnson & Johnson has conducted a careful review of the environment for innovative medicines in Norway.  As a result, we have decided to change the operating model for our Innovative Medicine business in Norway and wind down local commercial activity. 
We will continue to supply our medicines, support continuity of treatment for patients and complete all ongoing clinical trials. We will also review whether to initiate new clinical trials in Norway in the future.
We will manage this transition responsibly and remain open to constructive dialogue on creating an environment that supports timely patient access to medical innovation.